Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767899 | 0.90 | TSHR (0.45) | NPC1RAB9ATSHRLMNASMN1; SMN2 | |
| SCHEMBL3626606 | 0.86 | HSD11B1 (0.45) | NPC1RAB9ATSHRMIFSIRT1 | |
| SCHEMBL2767357 | 0.83 | NPC1 (0.59) | NPC1RAB9ATSHRLMNAMIF | |
| SCHEMBL123442 | 0.81 | NPC1 (0.41) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL24398605 | 0.81 | MIF (0.44) | NPC1RAB9ATSHRLMNASMN1; SMN2 | |
| SCHEMBL2765855 | 0.81 | MIF (0.63) | NPC1RAB9AMEN1KMT2AMIF | |
| SCHEMBL3625864 | 0.81 | MAOA (0.44) | NPC1RAB9ALMNASMN1; SMN2MAOA | |
| SCHEMBL3552703 | 0.79 | SNRNP200 (0.52) | MAOAMAOB | |
| SCHEMBL3626605 | 0.78 | MGLL (0.41) | NPC1RAB9ATSHRLMNASMN1; SMN2 | |
| SCHEMBL2765545 | 0.78 | MIF (0.53) | NPC1RAB9ALMNASMN1; SMN2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3142665-B1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | APAXEN (BE) | 2021-01-20 | — | — | EP | disclosed |
| CN-110218217-B | Benzoxazine-2-keto-benzo-imidazole compound and preparation method and application thereof | 湖南科技大学 | 2020-08-14 | — | — | CN | disclosed |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-09-11 | — | — | US | disclosed |
| EP-2944310-B1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| EP-3142665-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Mifcare (FR) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173433-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIFCARE (FR) | 2015-11-19 | — | — | WO | disclosed |
| EP-2944310-A1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | Mifcare (FR) | 2015-11-18 | — | — | EP | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | NPC1 2226/4885RAB9A 4733/4885TSHR 2363/4885 |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIF, CCL11, PGF | NPC1 2037/4885RAB9A 4745/4885TSHR 2496/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | NPC1 2037/4885RAB9A 4745/4885TSHR 2496/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | NPC1 4383/4885RAB9A 4105/4885TSHR 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.